136 related articles for article (PubMed ID: 22505209)
1. Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice.
Hsu YC; Huang HP; Yu IS; Su KY; Lin SR; Lin WC; Wu HL; Shi GY; Tao MH; Kao CH; Wu YM; Martin PE; Lin SY; Yang PC; Lin SW
Hepatology; 2012 Nov; 56(5):1913-23. PubMed ID: 22505209
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
3. Antinecrotic and antiapoptotic effects of hepatocyte growth factor on cholestatic hepatitis in a mouse model of bile-obstructive diseases.
Li Z; Mizuno S; Nakamura T
Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G639-46. PubMed ID: 17068118
[TBL] [Abstract][Full Text] [Related]
4. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice.
Giebeler A; Boekschoten MV; Klein C; Borowiak M; Birchmeier C; Gassler N; Wasmuth HE; Müller M; Trautwein C; Streetz KL
Gastroenterology; 2009 Jul; 137(1):297-308, 308.e1-4. PubMed ID: 19208365
[TBL] [Abstract][Full Text] [Related]
5. Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes.
Nakayama M; Sakai K; Yamashita A; Nakamura T; Suzuki Y; Matsumoto K
Cytokine; 2013 Jun; 62(3):446-52. PubMed ID: 23618918
[TBL] [Abstract][Full Text] [Related]
6. Immunolocalization of hepatocyte growth factor and its receptor (c-Met) during mouse liver development.
Ishikawa KS; Masui T; Ishikawa K; Shiojiri N
Histochem Cell Biol; 2001 Nov; 116(5):453-62. PubMed ID: 11735009
[TBL] [Abstract][Full Text] [Related]
7. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease.
Wu Q; Yu D; Post J; Halks-Miller M; Sadler JE; Morser J
J Clin Invest; 1998 Jan; 101(2):321-6. PubMed ID: 9435303
[TBL] [Abstract][Full Text] [Related]
9. Hepsin: a multifunctional transmembrane serine protease in pathobiology.
Li S; Wang L; Sun S; Wu Q
FEBS J; 2021 Sep; 288(18):5252-5264. PubMed ID: 33300264
[TBL] [Abstract][Full Text] [Related]
10. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
11. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice.
Wen J; Matsumoto K; Taniura N; Tomioka D; Nakamura T
Cancer Gene Ther; 2004 Jun; 11(6):419-30. PubMed ID: 15017381
[TBL] [Abstract][Full Text] [Related]
12. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
[TBL] [Abstract][Full Text] [Related]
13. Hepsin enhances liver metabolism and inhibits adipocyte browning in mice.
Li S; Peng J; Wang H; Zhang W; Brown JM; Zhou Y; Wu Q
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12359-12367. PubMed ID: 32404422
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes.
Monga SP; Mars WM; Pediaditakis P; Bell A; Mulé K; Bowen WC; Wang X; Zarnegar R; Michalopoulos GK
Cancer Res; 2002 Apr; 62(7):2064-71. PubMed ID: 11929826
[TBL] [Abstract][Full Text] [Related]
15. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
[TBL] [Abstract][Full Text] [Related]
16. Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice.
Apte U; Zeng G; Muller P; Tan X; Micsenyi A; Cieply B; Dai C; Liu Y; Kaestner KH; Monga SP
Hepatology; 2006 Oct; 44(4):992-1002. PubMed ID: 17006939
[TBL] [Abstract][Full Text] [Related]
17. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Li W; Wang BE; Moran P; Lipari T; Ganesan R; Corpuz R; Ludlam MJ; Gogineni A; Koeppen H; Bunting S; Gao WQ; Kirchhofer D
Cancer Res; 2009 Nov; 69(21):8395-402. PubMed ID: 19843851
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
[TBL] [Abstract][Full Text] [Related]
19. Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Tervonen TA; Belitškin D; Pant SM; Englund JI; Marques E; Ala-Hongisto H; Nevalaita L; Sihto H; Heikkilä P; Leidenius M; Hewitson K; Ramachandra M; Moilanen A; Joensuu H; Kovanen PE; Poso A; Klefström J
Oncogene; 2016 Apr; 35(14):1832-46. PubMed ID: 26165838
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
Hashimoto T; Kato M; Shimomura T; Kitamura N
FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
